



UNIVERSITY OF LEEDS

This is a repository copy of *Receipt and use of spoken and written over-the-counter medicine information: insights into Australian and UK consumers' experiences*.

White Rose Research Online URL for this paper:
<http://eprints.whiterose.ac.uk/118985/>

Version: Accepted Version

Article:

Tong, V, Raynor, DK orcid.org/0000-0003-0306-5275 and Aslani, P (2018) Receipt and use of spoken and written over-the-counter medicine information: insights into Australian and UK consumers' experiences. *International Journal of Pharmacy Practice*, 26 (2). pp. 129-137. ISSN 0961-7671

<https://doi.org/10.1111/ijpp.12382>

© 2017 Royal Pharmaceutical Society. This is the peer reviewed version of the following article: Tong, V. , Raynor, D. K. and Aslani, P. (2018), Receipt and use of spoken and written over-the-counter medicine information: insights into Australian and UK consumers' experiences. *Int J Pharm Pract*, 26: 129-137., which has been published in final form at <https://doi.org/10.1111/ijpp.12382>. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving. Uploaded in accordance with the publisher's self-archiving policy.

Reuse

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>

1 **Receipt and use of spoken and written over-the-counter medicine**
2 **information: insights into Australian and UK consumers' experiences**

3 **Abstract**

4 *Objectives*

5 To explore Australian and UK consumers' receipt and use of spoken and written medicine
6 information, and examine the role of leaflets for consumers of OTC medicines.

7 *Methods*

8 Semi-structured interviews were conducted with 37 Australian and 39 UK consumers to
9 explore information received with their most recent OTC medicine purchase, and how
10 information was used at different times post purchase. Interviews were audio-recorded,
11 transcribed verbatim, and thematically analysed.

12 *Key findings*

13 Similarities were evident between the key themes identified from Australian and UK
14 consumers' experiences. Consumers infrequently sought spoken information, and reported
15 that pharmacy staff provided minimal spoken information for OTC medicines. Leaflets were
16 not always received or wanted and had a less salient role as an information source for
17 repeat OTC purchases. Consumers tended not to read OTC labels or leaflets. Product
18 familiarity led to consumers tending not to seek information on labels or leaflets. When
19 labels were consulted, directions for use were commonly read. However, OTC medicine
20 information in general was infrequently revisited.

21 *Conclusions*

22 As familiarity is not an infallible proxy for safe and effective medication use, strategies to
23 promote the value and use of these OTC medicine information sources are important and
24 needed. Minimal spoken information provision coupled with limited written information use
25 may adversely impact medication safety in self-management.

26 *Keywords*

27 Drug labelling; non-prescription drugs; information seeking behaviour; consumer health
28 information; written information

29 Introduction

30

31 An increasing move towards the rescheduling of prescription medicines to over-the-counter
32 (OTC) status has become apparent over the years, fuelled by various factors such as self-
33 medication, consumerism, and the desire to direct health care costs to consumers.^[1, 2] As
34 OTC medication use is prevalent among consumers,^[3, 4] facilitation of safe and effective OTC
35 medication use requires availability, access, and utilisation of high quality spoken and
36 written medicine information (WMI).

37 Spoken and WMI may be utilised by consumers of OTC medicines, and the sources of such
38 information include pharmacists,^[5-9] OTC medicine labels,^[3, 5, 9-12] and leaflets.^[5, 8, 12-14]
39 Specific consumer OTC medicine information needs encompass directions for use, side
40 effects, drug interactions, and medicine efficacy,^[5] which have been addressed through the
41 use of OTC labels.^[15] However, OTC medicine information available at the point of purchase
42 can vary. Consultations with pharmacy staff may take place at the point of purchase.^[16-18]
43 However, inconsistencies in the provision of spoken information exist,^[19] such as between
44 first-time and repeat purchases,^[20] or different OTC medicines.^[21, 22] Issues with limited
45 information recall of spoken information,^[23] in addition to availability of OTC medicines in
46 retail settings where a health care professional is not available, can also impact OTC
47 medication safety.

48 Previous research has focussed on consumer advice seeking^[22] or advice received and/or
49 sought by consumers when the medicine was being purchased,^[7, 19, 20, 24, 25] or the advice
50 used,^[23] in relation to spoken OTC medicine information. Not all consumers actively sought
51 spoken advice about OTC medicines in the pharmacy.^[19, 22] However, a large proportion
52 reported receiving spoken information, and were satisfied with the information received.^{[7,}
53 ^{25]} Interviews conducted by Blom and Rens^[5] over 25 years ago regarding spoken and WMI
54 found that although spoken information was only provided for about one third of
55 purchases, further information was not wanted by the vast majority.^[5] WMI leaflets were
56 not requested by consumers, with only a minority reading WMI received.^[5] There has been
57 a dearth of recent qualitative research into consumers' experiences regarding OTC medicine
58 information receipt and use.

59 Reported readership of OTC labels varies significantly, from high readership^[9, 15] to low
60 readership exhibited for certain information such as possible side effects.^[3, 26] Furthermore,
61 OTC leaflet provision and availability differs between regulatory contexts. For example,
62 leaflets must be available with all medicines as package inserts in the European Union.^[27]
63 However, in Australia, leaflets are only required by law for a subset of OTC medicines known
64 as Pharmacist Only medicines.^[28] Hence, such differences can impact consumers' OTC
65 medicine information seeking, receipt, and use in self-management. To date, there is limited
66 insight into the role of leaflets as sources of OTC medicine information for OTC medicine
67 users and comparisons of their role between countries where their obligatory availability
68 differs, such as Australia and the UK. Furthermore, limited research has qualitatively
69 explored and compared consumers' receipt and use of spoken and written OTC medicine
70 information between two countries that differ in WMI availability. Therefore, this study
71 aimed to qualitatively explore Australian and UK consumers' receipt and use of spoken and
72 WMI for OTC medicines, and; examine the perceived and actual role of leaflets for
73 consumers of OTC medicines.

74

75 **Methods**

76

77 The present study was part of a larger international research collaboration which evaluated
78 the usability of existing labels and leaflets for OTC medicines in Australia and the UK through
79 the method of user testing. The study described here explored how consumers have sought,
80 received, and used information about OTC medicines. Ethics approval was granted by the
81 Human Research Ethics Committee of Institution A [2012/2865], and the Research Ethics
82 Committee of Institution B [SHREC/RP/343]. All participants provided written informed
83 consent and were reimbursed.

84

85 *Recruitment and interview sampling frame*

86 Individual, face-to-face semi-structured interviews were utilised to address the study aims,
87 as it is a qualitative method that allows for individuals' experiences to be explored and
88 elaborated upon in more detail.^[29] Interviews took place between April 2013 and April 2014
89 in Sydney, Australia and Leeds, UK at either Institution A (Australia) or the spin-out company
90 (UK).

91 Potential Australian participants were recruited using recruitment flyer distribution, online
92 advertisements, and a market research company. Interested individuals directly contacted
93 the researcher (Author 1) via the contact details provided on the recruitment flyers/online
94 advertisements. The market research company recruited participants via their consumer
95 database. All potential participants first spoke to Author 1 over the telephone for further
96 information about the study. If they were still interested in participating, they were
97 screened to confirm their eligibility in accordance with the inclusion and exclusion criteria.
98 Once eligibility was confirmed, an interview time was arranged.

99 Recruitment of UK participants was completed through the identification of potential
100 participants from the consumer database of a spin-out company from Institution B which
101 develops, refines and tests health information. The researcher telephoned potential
102 participants, explained the research study, and ascertained their interest in participating. If
103 interested, they were screened for eligibility using the inclusion and exclusion criteria, and if

104 eligible to participate, an interview time was arranged for those who agreed to come to the
105 purpose-built interview suite in the company offices.

106 Consumers were able to participate if they:

- 107 • Were 18 years or above,
- 108 • Were able to understand and communicate in English without the assistance from a
109 translator, and
- 110 • Had bought and used an OTC medicine, either for themselves or someone they cared
111 for, within the 6 month period immediately preceding study participation.

112 Consumers were ineligible if they:

- 113 • Were a health care professional (currently practising or retired),
- 114 • Utilised medicine information as a key part of their occupation, or
- 115 • Had significant cognitive or visual impairment which could impact study
116 participation.

117

118 *Interview protocol*

119 All interviews were conducted by the same female researcher (Author 1). Each face-to-face
120 session lasted approximately 1 hour and addressed a number of broader study aims. The
121 interviewer took care to remain as unbiased as possible throughout the conduct of the
122 interviews to help encourage open dialogue and dissuade socially desirable responses by
123 participants.

124 All participants were required to complete tasks related to the user testing of OTC medicine
125 information for either diclofenac or pholcodine.^[30] Participants were next prompted to
126 reflect upon their most recent purchase of an OTC medicine from a pharmacy (to minimise
127 recall bias), and were asked to elaborate on the information received and used in relation to
128 this purchase (Table 1). The interview protocol questions were developed and organised to
129 reflect the treatment continuum i.e. from the point of purchase to after the medicine had
130 been used. As part of the semi-structured interview protocol, probe questions were also
131 used when needed to encourage further elaboration of the participants' recalled
132 experiences, and their opinions and beliefs. This aimed to capture how OTC medicine

133 information was used by consumers at different points. The user testing of an OTC label and
134 leaflet in the initial part of the interview was intended to aid recall and help stimulate
135 consumers' reflections on their actual use of information about OTC medicines for
136 themselves or person(s) under their care.

137

138 *Data analysis*

139 With consent, all interviews were audio-recorded and verbatim transcriptions of the
140 interview audio recordings were completed. An incomplete recording was obtained for 1 UK
141 interview due to audio-recording device malfunction; only the available data were
142 transcribed. Resultant transcripts were then compared to the original audio recordings for
143 transcription quality assurance purposes and familiarisation with the interview data.

144 Thematic analysis^[31] of the finalised transcripts was then conducted by the interviewer
145 (Author 1). The Australian and UK interviews were initially treated as two distinct data sets
146 and analysed separately. Analysis of a portion of the transcripts was independently verified
147 by a second researcher (Author 3). Preliminary data analysis involved systematically re-
148 reading each transcript, and data were transposed into a matrix display^[32] to support the
149 ease of comparisons between interviews. A secondary matrix display was constructed to
150 help further consolidate and refine the analysis to aid in the identification of both trends
151 and discrepancies within and between the Australian and UK cohorts. Themes and
152 subthemes were inductively derived, refined, and discussed within the research team. From
153 the analyses, data saturation^[33] in both the Australian and UK interview cohorts was
154 determined to be achieved after 32 and 34 interviews, respectively.

155

156 **Results**

157

158 Semi-structured interviews were conducted with 37 Australian and 39 UK consumers (Table
159 2). A range of OTC medicines for various conditions were recently purchased (Table 3).

160 Although both first-time and repeat purchases were made, the majority of the most recent
161 OTC medicine purchases were repeat purchases. Clear trends in information seeking
162 behaviours were apparent among both Australian and UK cohorts. As a result, the findings
163 have been pooled for reporting here, and any distinct findings between the cohorts have
164 been separately reported, where applicable.

165

166 *OTC medicine information used and/or received at the point of purchase*

167 *Active consumer seeking of spoken and/or written OTC medicine information*

168 Minimal active seeking of spoken information was reported by consumers, where many
169 consumers would essentially just obtain the product required and complete the purchase, in
170 particular for repeat purchases (Table 4, participant quotes 1 and 2). A few participants read
171 the label at the point of purchase and did not actively seek spoken information.

172

173 *Receipt of spoken OTC medicine information*

174 The majority of both Australian and UK consumers reported that no spoken information was
175 actively provided when they purchased their most recent OTC product. Where received,
176 spoken information seemed to be associated more so with symptom-based requests, first-
177 time purchases, or if the consumer directed question(s) to the pharmacist or pharmacy staff
178 member (Table 4, participant quotes 3 and 4). Where spoken information was reported (by
179 a minority of participants), directions for use was the most often reported information
180 received. Other spoken advice given included difference(s) between proprietary products,
181 reassurance that the product would be appropriate for the presenting symptoms, use with
182 other medicine(s), how long until symptoms would be relieved, side effect(s), action to be
183 taken if side effect(s) or worsening of condition experienced, and expiry (UK). Interestingly,

184 a few consumers reported that little or no spoken information was provided by pharmacists
185 with first-time purchases they made.

186

187 *Perceptions on spoken OTC medicine information*

188 Assistance from pharmacy staff or spoken information was declined by a few consumers for
189 repeat purchases, where it was believed that there was no added value of spoken
190 information (Table 4, participant quote 5). Participants believed that minimal information
191 was provided if it was ascertained that the OTC product was a repeat purchase (Table 4,
192 participant quote 6). However, a UK consumer voiced surprise from the lack of questioning
193 associated with his most recent purchase, with no further spoken information provided.

194

195 *Written medicine information (WMI) use post OTC medicine purchase*

196 Consumers tended not to read OTC labels and/or leaflets if they were familiar with the
197 medicine. However, when WMI was used, directions for use were commonly read on the
198 label at home. Other information that was read (on the label, leaflet, or both) included
199 medicine strength, indication(s)/purpose, warnings, side effects, if alcohol or other
200 medicines could be used whilst taking the medicine, storage, ingredients (Australia),
201 medicine name/brand (UK), expiry date (Australia). Where the leaflet was used specifically,
202 consumers read information pertaining to side effects, warnings, directions for use (UK), use
203 with current medicines or alcohol (UK), or medicine strength (UK).

204 OTC labels and leaflets were not often revisited. For the Australian cohort specifically, the
205 small proportion who did revisit the accompanying OTC WMI at other points after its
206 purchase tended to be first-time medicine users. Directions for use were the most common
207 information revisited in both Australian and UK cohorts. In addition, an Australian consumer
208 noted that information was revisited if the symptoms were not resolving (Table 4,
209 participant quote 7).

210

211

212 *Factors contributing to minimal use of OTC WMI*

213 Lack of utilisation of OTC WMI was observed with consumer familiarity with the OTC
214 medicine (Table 4, participant quotes 8 and 9). Additionally, the known benefits of the OTC
215 medicine seemed to outweigh the perceived need to seek detailed OTC medicine
216 information (Table 4, participant quote 10).

217 A UK consumer who was taking regular low dose aspirin based on their doctor's
218 recommendation stated that *"because I've been told I would have to take it, I didn't really*
219 *think there was any need to go into it."* (UTP62-UK)

220 Other reasons that contributed to the lack of OTC WMI revisitation included success in
221 resolving the condition or symptoms, thus not requiring re-reading of the WMI, and/or
222 short treatment duration.

223

224 *Actual and perceived role of leaflets in self-management using OTC medicines*

225 The majority of Australian consumers reported that they did not receive a leaflet with their
226 most recent OTC purchase. In contrast, the overwhelming majority of UK consumers noted
227 receiving a leaflet. Specifically, UK consumers commented that leaflet receipt was standard,
228 where there was an inherent expectation that one would be available as a package insert.

229 Regardless of differences in leaflet receipt, many consumers in both Australia and the UK
230 did not want a leaflet with their most recent OTC purchase. Reported contributing factors
231 included:

- 232 • The consumer had experience and was familiar with the OTC medicine (i.e. repeat
233 purchase) (Table 4, participant quote 11),
- 234 • Information needs were met by other information source(s), such as the label,
235 and/or
- 236 • The medicine was regarded as essentially safe for use.

237 Conversely, some participants did want leaflets with their most recent purchase e.g. if
238 unfamiliar with the medicine, or more self-management information was wanted
239 (Australia). Other reasons included wanting to know about side effects, or in case of a
240 change in medical conditions (UK) (Table 4, participant quote 12).

241 Although leaflets were not perceived as a desired OTC medicine information source in
242 relation to their most recent purchases, some participants did indicate that leaflets could be
243 useful and needed for first-time purchases (Table 4, participant quote 13).
244 Specifically, leaflets were regarded as an information source to be utilised on an as-needed
245 basis; for instance, in the event of any queries or problems encountered (Table 4,
246 participant quotes 14 and 15). If an OTC medicine was effective or a doctor had “prescribed”
247 its use, there was an assumption that the leaflet did not need to be read.

248

249 **Discussion**

250

251 Common trends in consumers’ seeking, receipt, and use of OTC medicine information
252 between Australia and the UK were evident. Australian and UK participants did not often
253 read OTC labels and leaflets in detail, particularly for repeat purchases. When labels were
254 read post purchase, directions for use were the most commonly read. Overall, consumers’
255 familiarity with a product was associated with less active spoken and written OTC medicine
256 information seeking. Furthermore, the degree of consumer-initiated interactions appeared
257 to impact the provision of spoken information. Leaflets were not wanted by many due to
258 consumers’ perceptions of the safety of OTC medicine(s), but may have a more salient role
259 for first-time purchases.

260 There are some study limitations to consider. As this was a qualitative investigation, the
261 study findings are not generalisable, nor were they intended to be. However, they do
262 provide insights into common behaviours associated with information seeking and use
263 which should be considered in a self-management context. Despite discussions being
264 centred on participants’ most recent OTC purchases, a degree of recall bias may still be
265 present, even with the specific interview session structure intended to help reduce its
266 impact. Furthermore, as the study focussed on OTC purchases from pharmacies, consumers’
267 experiences relating to purchases made on the Internet or from other retail settings were
268 not explored. With the range of study participant ages and education levels, participant
269 health literacy levels are also likely to differ within cohorts. However, as health literacy was
270 not screened, those with poor health literacy may be underrepresented in this study.

271 Finally, voluntary participation in the study may have led to some degree of self-selection of
272 the participants, potentially impacting the range of consumers interviewed.

273 A recent systematic review conducted by van Eikenhorst et al.^[34] also noted inconsistencies
274 in spoken information provision in pharmacies. Non-receipt of spoken information by the
275 majority of consumers in relation to their most recent OTC purchase is an important finding
276 of the present study in terms of pharmacy practice and the promotion of quality use of
277 medicines. Although some previous studies reported the majority receiving spoken
278 information for purchased OTC medicine(s),^[7, 25] this may be related to the requirement for
279 consumers to speak to the pharmacist to purchase the OTC medicine,^[7] as these studies
280 related to OTC medicines only available for purchase in pharmacies.^[7, 25] From the present
281 study findings, repeat OTC purchases in particular seem to be associated with limited
282 spoken information provided by pharmacy staff and limited consumer information seeking.
283 Thus, the interplay between spoken information provision and the degree to which it is
284 dependent on consumer initiation of this exchange (via active advice seeking) has an
285 influence on the OTC medicine information that is received and used by consumers. The
286 influence of perceived OTC product familiarity on expectations about spoken exchanges
287 with pharmacy staff were also echoed previously by parents and/or carers,^[19] and was a
288 primary reason cited by consumers for not receiving spoken advice.^[25] Consumers may not
289 always actively seek OTC medicine information from health care professionals, such as
290 pharmacists, or in the pharmacy, as seen in both the present study and the literature.^[8, 22, 26]
291 This may be attributed to reasons such as a lack of perceived need,^[8] the medicine had been
292 used before,^[22] or that consumers' information needs had already been met,^[3] which is
293 consistent with the current identified Australian and UK trends in OTC medicine information
294 seeking behaviours. Importantly, suboptimal interactions between pharmacy staff and
295 consumers may result in the inappropriate provision of OTC medicines.^[35] Symptom-based
296 requests are known to be handled more proficiently than direct product requests in a
297 pharmacy setting,^[36] with limited provision of spoken information also seen in relation to
298 simulated OTC direct product requests.^[37, 38] Ultimately, inconsistencies in spoken OTC
299 medicine information provision and receipt may lead to suboptimal consumer self-
300 management.

301 Reported patterns of OTC WMI use in the present study somewhat differed to previous
302 research, where a clear majority of consumers have reported reading the label,^[9, 11] leaflet
303 (when available with the purchased OTC medicine),^[8] or both.^[15] However, this high OTC
304 label readership was reported in relation to first-time OTC medicine purchases,^[9, 11] rather
305 than repeat purchases. The pervasive belief that OTC medicines are safe,^[11] or not strong
306 enough to be problematic,^[3] could potentially encourage decreased OTC medicine
307 information use for some, as reflected in why a leaflet was not wanted in this study. As
308 consumers may take inappropriate doses or have inadequate understanding of self-
309 management strategies specific to the condition for which OTC medicines are utilised,^[39]
310 this emphasises the importance of receiving information regardless of whether it has been
311 sought. Information seeking behaviour is inherently dynamic; however, consumers may not
312 realise the extent or nature of gaps in knowledge or understanding that would prompt them
313 to seek information needed to facilitate safe self-management. Importantly, perceived
314 familiarity or confidence in using an OTC medicine should not be mistaken for, or equated
315 to, actual engagement in safe and appropriate OTC medication use in all circumstances. In
316 addition, wider access to OTC medicines may not lead to maintained levels of appropriate
317 use, as seen in the decline in the proportion appropriately using OTC ibuprofen as per the
318 label since scheduling changes no longer restricted its sale to pharmacies only.^[40]

319 Leaflets were not commonly reported as a routinely used or desired OTC medicine
320 information source by Australian and UK consumers. When examining consumer
321 perceptions on leaflets for OTC medicines, UK consumers' desire for leaflets was somewhat
322 unrelated to past receipt or expectation of receiving one. In countries like Australia, limited
323 compulsory leaflet availability for OTC medicines^[28] may impact its potential role as an
324 information source and increase the demands on the label to adequately convey key points.
325 Therefore, limited perceived need or availability of leaflets heightens the need for OTC
326 labels to be of high usability, in particular for first-time purchases. Key stakeholders such as
327 regulators and the pharmaceutical industry have a responsibility to ensure the provision of
328 high quality, user-friendly medicine information that is useful for consumers at all points in
329 the treatment continuum.

330

331 **Conclusion**

332

333 Commonalities exist between Australian and UK consumers' reported spoken and written
334 OTC medicine information seeking and use regardless of inter-country differences in the
335 written information provided with OTC medicines. Consumers' familiarity with OTC
336 medicine(s) appeared to moderate spoken information provision as well as consumer
337 information seeking behaviours. Repeat OTC purchases were associated with reduced OTC
338 medicine information seeking and use. Passive receipt of OTC leaflets did not always
339 correlate to the information source being desired by consumers. Minimal spoken
340 information provision at the point of purchase coupled with limited use of WMI for OTC
341 medicines may impact medication safety in self-management. These observed trends in OTC
342 medicine information seeking behaviours will be useful to consider when developing
343 consumer-centred initiatives to strategically promote safe and effective self-management
344 undertaken by consumers of OTC medicines.

345

346

347

348 **References**

349

- 350 1. Blenkinsopp A, Bradley C. Patients, society, and the increase in self medication. *BMJ*
351 1996; 312: 629-632.
- 352 2. Schondelmeyer SW. Economic aspects of switch. *Drug Inf J* 1990; 24: 57-66.
- 353 3. Harris Interactive Inc. Attitudes and beliefs about the use of over-the-counter
354 medicines: a dose of reality; a national survey of consumers and health professionals, 2002.
- 355 4. Koslow S. *Consumer behaviour fact book: understanding consumers' use and*
356 *attitudes towards OTC medicines, vitamins, minerals and supplements*. Sydney: Macquarie
357 University, 2015.
- 358 5. Blom ATG, Rens JAL. Information about over-the-counter medication: the role of the
359 pharmacy. *Patient Educ Couns* 1989; 14: 181-189.
- 360 6. Newby DA et al. Drug information for consumers: should it be disease or medication
361 specific? Results of a community survey. *Aust New Zeal J Publ Health* 2001; 25: 564-570.
- 362 7. Simoens S et al. Patient experiences of over-the-counter medicine purchases in
363 Flemish community pharmacies. *Pharm World Sci* 2009; 31: 450-457.
- 364 8. Albarrán KF, Zapata LV. Analysis and quantification of self-medication patterns of
365 customers in community pharmacies in southern Chile. *Pharm World Sci* 2008; 30: 863-868.
- 366 9. Taylor J et al. Consumer over-the-counter usage and attitudes: a survey in one
367 Canadian city. *Int J Pharm Pract* 2008; 16: 295-302.
- 368 10. Gray NJ et al. 'Health repertoires': an understanding of lay management of minor
369 ailments. *Patient Educ Couns* 2002; 47: 237-244.
- 370 11. Bolaños H. Responsible self-medication in Latin America. *Drug Inf J* 2005; 39: 99-107.
- 371 12. Gray NJ et al. Information sources used by parents buying non-prescription
372 medicines in pharmacies for preschool children. *Int J Clin Pharm* 2011; 33: 842-848.
- 373 13. Birchley N, Conroy S. Parental management of over-the-counter medicines. *Paediatr*
374 *Nurs* 2002; 14: 24-28.

- 375 14. Cuzzolin L, Benoni G. Safety of non-prescription medicines: knowledge and attitudes
376 of Italian pharmacy customers. *Pharm World Sci* 2010; 32: 97-102.
- 377 15. Nabors LA et al. Reading about over-the-counter medications. *Issues Compr Pediatr*
378 *Nurs* 2004; 27: 297-305.
- 379 16. Emmerton LM. Exploration of two risk scenarios in non-prescription medicine
380 purchases. *Int J Pharm Pract* 2006; 14: 219-225.
- 381 17. Emmerton L. The 'third class' of medications: sales and purchasing behavior are
382 associated with pharmacist only and pharmacy medicine classifications in Australia. *J Am*
383 *Pharm Assoc (2003)* 2009; 49: 31-37.
- 384 18. Emmerton L, Shaw J. The influence of pharmacy staff in non-prescription medicine
385 sales. *Int J Pharm Pract* 2002; 10: 101-106.
- 386 19. Boardman HF et al. Interactions between parents/carers of pre-school children and
387 pharmacy staff when buying non-prescription medicines. *Int J Clin Pharm* 2011; 33: 832-841.
- 388 20. John DN, Evans SW. Residents' views and experiences of pharmacy questioning and
389 advice relating to non-prescription medicine purchases. *Int J Pharm Pract* 1997; 5: 85-90.
- 390 21. Kelly FS et al. Does advice from pharmacy staff vary according to the nonprescription
391 medicine requested? *Ann Pharmacother* 2009; 43: 1877-1886.
- 392 22. Taylor J. Reasons consumers do not ask for advice on non-prescription medicines in
393 pharmacies. *Int J Pharm Pract* 1994; 2: 209-214.
- 394 23. Evans SW et al. Use of non-prescription advice offered to the public by community
395 pharmacists. *Int J Pharm Pract* 1997; 5: 16-25.
- 396 24. Hassell K et al. Advice provided in British community pharmacies: what people want
397 and what they get. *J Health Serv Res Policy* 1998; 3: 219-225.
- 398 25. Healthcare Management Advisors. Consumer perceptions on supply of and access to
399 Pharmacy medicines. Australia: The Pharmacy Guild of Australia, Australian Government
400 Department of Health and Ageing, n.d.
- 401 26. Ngo SNT et al. Appropriate use of non-prescription ibuprofen: a survey of patients'
402 perceptions and understanding. *Int J Pharm Pract* 2010; 18: 63-65.

- 403 27. European Commission. Directive 2001/83/EC of the European Parliament and of the
404 Council of 6 November 2001 on the Community code relating to medicinal products for
405 human use. Brussels: European Commission, 2001.
- 406 28. Aslani P. Consumer medicine information conundrums. *Aust Prescr* 2007; 30: 122-
407 124.
- 408 29. Britten N. Qualitative interviews. In: Pope C, Mays N, eds. *Qualitative Research in*
409 *Health Care*, 3rd edn. Oxford: Blackwell Publishing Ltd, 2006: 12-20.
- 410 30. Author citation 2015 (in press).
- 411 31. Green J, Thorogood N. *Qualitative Methods for Health Research*, 3rd ed. London:
412 SAGE Publications Ltd, 2014: 209-218.
- 413 32. Miles MB, Huberman AM. *Qualitative Data Analysis: An Expanded Sourcebook*, 2nd
414 ed. Thousand Oaks: SAGE Publications Inc., 1994.
- 415 33. Guest G et al. How many interviews are enough?: An experiment with data
416 saturation and variability. *Field Methods* 2006; 18: 59-82.
- 417 34. van Eikenhorst L et al. A systematic review in select countries of the role of the
418 pharmacist in consultations and sales of non-prescription medicines in community
419 pharmacy. *Res Social Adm Pharm* 2017; 13: 17-38.
- 420 35. Schneider CR et al. Evaluation of the supply of antifungal medication for the
421 treatment of vaginal thrush in the community pharmacy setting: a randomized controlled
422 trial. *Pharmacy Practice* 2013; 11: 132-137.
- 423 36. Benrimoj SI et al. Monitoring quality standards in the provision of non-prescription
424 medicines from Australian community pharmacies: results of a national programme. *Qual*
425 *Saf Health Care* 2007; 16: 354-358.
- 426 37. Schneider CR et al. Measuring the assessment and counseling provided with the
427 supply of nonprescription asthma reliever medication: a simulated patient study. *Ann*
428 *Pharmacother* 2009; 43: 1512-1518.
- 429 38. Kashyap KC et al. Management of over-the-counter insomnia complaints in
430 Australian community pharmacies: a standardized patient study. *Int J Pharm Pract* 2014; 22:
431 125-134.

432 39. Guirguis K. The use of nonprescription medicines among elderly patients with
433 chronic illness and their need for pharmacist interventions. *Consult Pharm* 2010; 25: 433-
434 439.

435 40. Stosic R et al. Responsible self-medication: perceived risks and benefits of over-the-
436 counter analgesic use. *Int J Pharm Pract* 2011; 19: 236-245.

437

438

Table 1. Core semi-structured interview protocol questions

Discussion point	Question(s)
Most recent medicine purchased	<ul style="list-style-type: none">• What medicine did you buy to use/give to someone under your care?
Medicine information provision at the point of purchase	<ul style="list-style-type: none">• When you were in the pharmacy about to buy it, what information was given to you about the medicine?• Who gave this information to you?
Written medicine information (WMI) provision	<ul style="list-style-type: none">• Did you receive a WMI leaflet with the medicine you bought to use?• Would you have liked to receive a WMI leaflet with your medicine? Why?
Information use after the medicine had been purchased	<ul style="list-style-type: none">• Once you bought the medicine, did you go home and read the information in the leaflet/on the box/both?• What were the key sections you looked at and why did you look at these sections in the leaflet or on the box?• Were there any other times that you needed to reread the box/leaflet? What did you look at?

444

Table 2. Summary of participant demographics

Demographic		Australia (n=37)	UK (n=39)	Total (n=76)
Gender	Male	19	19	38
	Female	18	20	38
Age (years)	18-29	10	8	18
	30-49	13	14	27
	50-69	12	10	22
	70+	2	7	9
Highest level of education attained	School Certificate/GCSE ^a (Year 10) or below	1	10	11
	Higher School Certificate/A Level ^b (Year 12) or college qualification	25	21	46
	Bachelor's degree or higher	11	8	19
Main language spoken at home	English	34	39	73
	Other	3	0	3
Country of birth	Australia	31	1	32
	UK	1	36	37
	Other	5	2	7

445 ^aGCSE = UK General Certificate of Secondary Education446 ^bA Level = UK General Certificate of Education Advanced Level

447

448

Table 3. Most recent OTC medicine purchases categorised by type

OTC medicine(s) purchased	Australia	UK	Total
Analgesic(s), non-steroidal anti-inflammatory, musculoskeletal product(s)	12	22	34
Respiratory (cough/cold/flu/allergy) product(s)	15	8	23
Dermatological product(s)	4	4	8
Oral/ear/eye product(s)	2	3	5
Gastrointestinal product(s)	1	1	2
Vitamin(s)/supplement(s)	7	1	8
Other	1	1	2
Total ^a	42	40	82

449

450 ^aA few participants purchased multiple OTC medicines in their most recent transaction, thus
 451 the total number of medicines purchases exceeded the total number of participants per
 452 cohort (n=37 [Australia] and n=39 [UK]).

Table 4. Identified theme(s)/subtheme(s) and illustrative participant quote(s)

Theme(s)/subtheme(s)	Illustrative quote(s)
Active consumer seeking of spoken and/or written OTC medicine information	<p>Quote 1: <i>“I have taken this medicine before so I don’t even bother to ask the pharmacist. Because I know, uh, which section [of the pharmacy] it is [in]. I just scan [the shelves] and [think] ‘Okay, yeah, this section.’ I’ve read [the labels of] all the syrups there.” (UTP20-AUS)</i></p> <p>Quote 2: <i>“Paracetamol being such a, a well-known brand…… I wouldn't actually wish to know anything about it, because I know what I've gone for. I've got headache. I know what I'm going to buy: paracetamol. So I would just go pick it off the shelf and pay for it.” (UTP51-UK)</i></p>
Receipt of spoken OTC medicine information	<p>Quote 3: <i>“Once they know you've used it before, they don't tend to give you any instructions.” (UTP09-AUS)</i></p> <p>Quote 4: <i>“They say ‘Have you taken it before?’, which the answer is yes. Then obviously, they assume that if there’s anything they should say to somebody taking it for the first time, I would already know that so ... As I say, in general, it’s just ‘Have you taken it before? Are you taking anything else with paracetamol and codeine?’ And ‘Don’t exceed the 4 a day of the tablets’.” (UTP71-UK)</i></p>
Perceptions on spoken OTC medicine information	<p>Quote 5: <i>“She offered to give me some advice, but I, I declined…… Because I've used those sorts of things before. So I didn't think she would be able to tell me anything I didn't know.” (UTP41-UK)</i></p> <p>Quote 6: <i>“They always ask me a sort of gateway type question; I can’t remember what it is now. And I always say ‘You know, so, yes. I’ve had it before.’ And then it’s just a matter of which size I want…… Once I’ve said I’ve... used it before, they don’t tend to give any further information.” (UTP09-AUS)</i></p>

Theme(s)/subtheme(s)	Illustrative quote(s)
Written medicine information (WMI) use post OTC medicine purchase	Quote 7: <i>"I think I looked at the box just a couple of times just to double check that it was the same thing because it didn't seem to be working..... Because I was like 'Damn you, cold sore. You're erupting on my face, still ...'" (UTP27-AUS)</i>
Factors contributing to minimal use of OTC	Quote 8: <i>"The first time around... on the advice of the chemist... I did it religiously and it was perfect. And since then, I've just taken them." (UTP03-AUS)</i>
WMI	Quote 9: <i>"No issues for me and I guess that's why I didn't speak to anyone. That's why I didn't look for any information because I'm familiar with the product. I'm familiar with the brand, I'm familiar with what it does to me and so I, I didn't really feel like I needed any more." (UTP07-AUS)</i>
	Quote 10: <i>"It's almost like lollies to relieve a sweet craving. I know they're going to work and I, I need them. It's more of a need than a desire to read anything. It's a desperation thing." (UTP03-AUS)</i>
Actual and perceived role of leaflets in self-management using	Quote 11: <i>"I always buy the same brand. So unless there is something new that they've put in the leaflet then yes, it's probably a waste of paper. 'Cause I, I do keep... I mean I've got one from the first time I take it, as with everything that I've taken. But ah, in general after that, it's, it's no longer necessary." (UTP71-UK)</i>
OTC medicines	Quote 12: <i>"Say if I had a stomach ulcer but the last time I took it, I didn't have a stomach ulcer. I would not have read that, because that was not relevant to me. Whereas, this time, I would've read the leaflet..... and see if it connects to me." (UTP54-UK)</i>

Theme(s)/subtheme(s) Illustrative quote(s)

Quote 13: "As a new user, I probably would [want a leaflet]. You know, I'd want to know the effects... But because I've been using it for a number of years... it's just something that's in the way of the product." (UTP68-UK)

Quote 14: "I rarely read the leaflets. It's only if I'm looking for something specific that I'll read a leaflet." (UTP09-AUS)

Quote 15: "Um, I don't think it does any harm to have the leaflet because even if you've read it before you might not have kept it. So if you have any sort of weird reaction to anything, you can have the leaflet there. I think it's important to have a leaflet every time because in case you don't um ... you haven't kept the last one." (UTP64-UK)